A local organisation announced it will develop an Ebola vaccine dubbed the “most promising” to fight back against a deadly outbreak in the Democratic Republic of Congo.
Nearly 1,500 people have died in the conflict-wracked African country from the Bundibugyo strain of Ebola, for which there are no vaccines or treatments.
But there are several different efforts racing to develop a vaccine for the previously rare strain in the hope of stemming the escalating outbreak.
World Health Organization experts have said a single-dose shot based on the rVSV platform is the “most promising” candidate.
The Singapore-based Hilleman Laboratories announced on Thursday it would advance the rVSV Bundibugyo jab so it can be tested on humans during trials.
A viral haemorrhagic fever, Ebola spreads through close contact and infected bodily fluids. — AFP
